These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27259515)

  • 1. MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?
    Leitzen C; Wilhelm-Buchstab T; Schmeel LC; Garbe S; Greschus S; Müdder T; Oberste-Beulmann S; Simon B; Schild HH; Schüller H
    Strahlenther Onkol; 2016 Jul; 192(7):481-8. PubMed ID: 27259515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of clinical course of glioblastomas by MRI during radiotherapy].
    Leitzen C; Schild HH; Bungart B; Herrlinger U; Lütter C; Müdder T; Wilhelm-Buchstab T; Schüller H
    Strahlenther Onkol; 2010 Dec; 186(12):681-6. PubMed ID: 21221885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma.
    Zschaeck S; Wust P; Graf R; Misch M; Onken J; Ghadjar P; Badakhshi H; Florange J; Budach V; Kaul D
    Radiat Oncol; 2018 Dec; 13(1):251. PubMed ID: 30567592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalated conformal radiotherapy of glioblastomas -- results of a retrospective comparison applying radiation doses of 60 and 70 Gy.
    Graf R; Hildebrandt B; Tilly W; Sreenivasa G; Ullrich R; Felix R; Wust P; Maier-Hauff K
    Onkologie; 2005 Jun; 28(6-7):325-30. PubMed ID: 15933420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
    Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
    Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
    Tselis N; Kolotas C; Birn G; Röddiger S; Filipowicz I; Kontova M; Fountzilas G; Selviaridis P; Baltas D; Heyd R; Anagnostopoulos G; Zamboglou N
    Strahlenther Onkol; 2007 Oct; 183(10):563-70. PubMed ID: 17896088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma and radiotherapy: A multicenter AI study for Survival Predictions from MRI (GRASP study).
    Chelliah A; Wood DA; Canas LS; Shuaib H; Currie S; Fatania K; Frood R; Rowland-Hill C; Thust S; Wastling SJ; Tenant S; McBain C; Foweraker K; Williams M; Wang Q; Roman A; Dragos C; MacDonald M; Lau YH; Linares CA; Bassiouny A; Luis A; Young T; Brock J; Chandy E; Beaumont E; Lam TC; Welsh L; Lewis J; Mathew R; Kerfoot E; Brown R; Beasley D; Glendenning J; Brazil L; Swampillai A; Ashkan K; Ourselin S; Modat M; Booth TC
    Neuro Oncol; 2024 Jun; 26(6):1138-1151. PubMed ID: 38285679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
    Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
    Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
    Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
    J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
    Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma.
    De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Cohen-Jonathan-Moyal E; Roux FE
    J Neurooncol; 2019 May; 142(3):489-497. PubMed ID: 30783874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.
    Anwar M; Molinaro AM; Morin O; Chang SM; Haas-Kogan DA; Nelson SJ; Lupo JM
    Radiat Res; 2017 Sep; 188(3):303-313. PubMed ID: 28723274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme.
    Lutterbach J; Weigel P; Guttenberger R; Hinkelbein W
    Radiother Oncol; 1999 Oct; 53(1):49-52. PubMed ID: 10624853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group].
    Boisserie G; Cornu P; Dormont D; Sahel M; Hardiman C; Tep B; Mandin AM; Barret C; Faillot T; Delattre JY; Monjour A; Poisson M; Marsault C; Philippon J; Simon JM; Baillet F; Mazeron JJ
    Bull Cancer Radiother; 1996; 83(3):144-52. PubMed ID: 8977564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy.
    Prados MD; Wara WM; Edwards MS; Larson DA; Lamborn K; Levin VA
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):85-91. PubMed ID: 7619124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy.
    Förster A; Böhme J; Maros ME; Brehmer S; Seiz-Rosenhagen M; Hänggi D; Wenz F; Groden C; Pope WB; Giordano FA
    J Neuroradiol; 2020 Mar; 47(2):166-173. PubMed ID: 30659892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irradiation fields and doses in glioblastoma multiforme: are current standards adequate?
    Reni M; Cozzarini C; Panucci MG; Ceresoli GL; Ferreri AJ; Fiorino C; Truci G; Falini A; Tartara F; Terreni MR; Verusio C; Villa E
    Tumori; 2001; 87(2):85-90. PubMed ID: 11401212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
    Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
    Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.